NFKB1 and colorectal carcinoma: In terms of therapeutic strategies, ginsenoside Rh4 inhibits CRC in a gut microbiota-dependent manner by regulating microbiota-mediated bile acid metabolism and promoting ursodeoxycholic acid production to modulate the NF-κB signaling pathway (60).